Inflammasome: development IL-1ß inhibitors

Opsona Therapeutics is developing compounds targeting the Inflammasome, strategically complementing our pipeline of innate immune modulators.

Pathologies such as gouty arthritis, Muckle-Wells syndrome (MWS) or CINCA have been shown to be dependent on Inflammasome activity. In vitro and in vivo experiments have been carried out to validate this as a target for an innovative drug development programme.  

Early development studies have confirmed drugability of the Inflammasome and its tremendous potential as a specific IL1-ß inhibitor.

Opsona is actively seeking a partnering opportunity for its small molecule Inflammasome modulator programme.